TAKHZYRO (LANADELUMAB-FLYO)
TAKHZYRO (LANADELUMAB-FLYO) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: TAKHZYRO; Generic name: LANADELUMAB-FLYO; Drug class: Plasma Kallikrein Inhibitor [EPC].
| Brand name | TAKHZYRO |
|---|---|
| Generic name | LANADELUMAB-FLYO |
| Drug class | Plasma Kallikrein Inhibitor [EPC] |
| Manufacturer | Takeda Pharmaceuticals America, Inc. |
| Used for | 1 INDICATIONS AND USAGE TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION For subcutaneous use only. Recommended Dosage: Adult and pediatric patients 12 years of age and older: administer 300 mg every 2 weeks by the patient or caregiver. Dosing interval every 4 weeks may be considered in some patients. ( 2.1 ) Pediatric patients 6 to less than 12 years of age: administer 150 mg every 2 weeks by a healthcare provider or caregiver. Dosing interval every 4 weeks may be considered in some patients. ( 2.2 ) Pediatric patients 2 to less than 6 ye |
| Active ingredient(s) | LANADELUMAB |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8 |